Faculty Bibliography

Background Despite increased cardiovascular mortality in patients with HIV, studies have shown suboptimal rates of statin prescription among qualifying patients. Our initial trainee needs assessment survey revealed a lack of comfort and modifiable barriers to prescribing statins to patients with CAD and HIV on anti-retroviral therapy (ART). We sought to create a tool to mitigate these barriers and improve comfort and self-reported practice in prescribing statins to this population. Methods A 1-page tool detailing statin-ART co-administration regimens, common drug interactions and potential side effects was created and introduced to 24 cardiology and 8 infectious disease fellows at NYU School of Medicine. Ten weeks later, a post-intervention survey was conducted to assess comfort, barriers, and self-reported practice when prescribing statins to patients with HIV. Data was de-identified by a 3^rd party. Results were excluded for lack of consent for study participation and incomplete and/or duplicate survey responses. Results Of the included 11 cardiology and 6 infectious disease fellows, 53% report using the tool in clinical decision making over 10 weeks. Of these, 78% report the tool increased comfort initiating and/or adjusting statin therapy and 89% report the tool increased overall comfort managing statins in patients with HIV. In our prior needs assessment survey, the majority of fellows cited one or more barriers to prescribing statins to patients with HIV and a minority reported always considering HIV status when deciding to initiate statin therapy. After introduction of the tool, however, over half of fellows report no barriers to prescribing statins to this population and 100% report they will now always consider HIV status when deciding to initiate statin therapy. Ultimately, 65% of fellows plan to use the 1-page tool in the future and 82% recommend that it be provided to future trainees. Conclusion Introduction and use of our 1-page tool improved trainee comfort, reduced known barriers, and improved self-reported practice when prescribing statins to patients with HIV. Integration of such a tool into the curriculum can improve trainee education in caring for a vulnerable population.
Copyright

Background. Despite the high efficacy of PrEP, it continues to be underutilized. We examined the extent to which patients with a documented positive test for STIs were provided PrEP at an urban municipal medical center. Methods. We reviewed data of all patients seen between January 1, 2014 and July 30, 2017 who were > 18 years old and had an initial HIV negative test and >=1 positive test for Chlamydia, Gonorrhea, or Syphilis. We examined PrEP prescription data by gender, race/ethnicity, and clinic location. Differences between groups were compared using Chi-squared analysis and logistic regression. Results. Of 1,142 initially HIV- patients who were identified as having a positive STI result, 52% were female, 89% either Black or Hispanic, with a median age of 40 years (quartiles 30, 47). 58% had Medicare/Medicaid and 34% were self-pay or uninsured (Table 1). Only 25 (2.1%) of 1,142 patients who had >=1 STI test positive were prescribed PrEP. No women received PrEP. Whites (aOR: 21.7 [95% CI:4.4, 107, P < 0.001] and Hispanics (aOR:6.64 [95% CI:1.35, 32.8, P = 0.02] were both more likely to receive PrEP than Blacks, after adjusting for age, sex, marital status, and insurance. All PrEP prescriptions originated from the Medicine, Emergency, or HIV specialty clinics although most STI testing was obtained in Emergency and Obstetrical/Gynecological clinics (Table 2). Conclusion. There were significant missed opportunities for HIV prevention among patients with STIs within the medical center, particularly among Hispanic and Black patients. Enrichment programs to educate providers and increase PrEP prescriptions may have a major impact on expanding HIV prevention, especially for women. (Figure Presented)

Pulmonary malignancies are a major source of morbidity and mortality in HIV-infected persons. Non-AIDS-defining lung cancers (mostly non-small cell lung cancers) are now a leading cause of cancer death among HIV-infected persons. HIV-associated factors appear to affect the risk of lung cancer and may adversely impact cancer treatment and outcomes. HIV infection also may modify the potential harms and benefits of lung cancer screening with computed tomography. AIDS-defining lung malignancies include pulmonary Kaposi sarcoma and pulmonary lymphoma, both of which are less prevalent with widespread adoption of antiretroviral therapy.